How do I buy Vaxcyte, Inc. Common Stock (PCVX) stock?

Buying Vaxcyte, Inc. Common Stock (PCVX) stock is now easy and instant through the Gotrade app. Download the Gotrade app from the App Store or Google Play. Create an account and verify your identity. Make a deposit. Search for the code "PCVX", then tap "Trade". Tap the "Buy" button. Enter the amount you want to buy. You have two options: Buy PCVX by number of shares. Buy fractional shares in dollars, starting from $1. Swipe up to confirm your order, and you're done!

What is the minimum investment for PCVX on Gotrade?

On Gotrade , you don't have to buy a full share. With fractional shares, you can start investing in Vaxcyte, Inc. Common Stock from just $1. A small budget shouldn't stop you from building a US stock portfolio.

Does Vaxcyte, Inc. Common Stock (PCVX) pay dividends?

At the moment, Vaxcyte, Inc. Common Stock (PCVX) does not pay dividends because it focuses on reinvesting profits for company growth (a growth stock). However, you can still potentially earn profit from share price increases (capital gains). Track PCVX's performance via the price chart in the Gotrade app.

Is buying PCVX on Gotrade safe and legal?

Gotrade is the trading name of Gotrade Securities Inc., which is registered with and supervised by the Labuan Financial Services Authority (LFSA).

What are the market hours to buy PCVX?

You can place an order any time. It goes through when the US market (NYSE/NASDAQ) opens: 9:30 AM to 4:00 PM New York time, Monday to Friday. Pre-market and after-hours trading are open too. The market is closed on US public holidays. The Gotrade app shows whether the market is open.

How do I tell if PCVX is expensive or cheap?

There's no single perfect answer, but common approaches include: Compare valuation (e.g., P/E, P/S) against historical averages or competitors. Review revenue and earnings growth. Check margins and cash flow. Evaluate business outlook and the company's position within its industry. You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Vaxcyte, Inc. Common Stock (PCVX) Stock Price: Nov 11 Close $68.62

Latest news

Zacks Investment Research

Wall Street Analysts See an 87.35% Upside in Vaxcyte (PCVX): Can the Stock Really Move This High?

PositivePCVXOctober 30, 2026

Zacks Investment ResearchPositive

Wall Street Analysts See an 87.35% Upside in Vaxcyte (PCVX): Can the Stock Really Move This High?

PCVX

Zacks Investment Research

Wall Street Analysts Think Vaxcyte (PCVX) Could Surge 75.6%: Read This Before Placing a Bet

PositivePCVXOctober 14, 2026

Zacks Investment ResearchPositive

Wall Street Analysts Think Vaxcyte (PCVX) Could Surge 75.6%: Read This Before Placing a Bet

PCVX

Investors Business Daily

Biotech Stocks Tumble, With Recent Winners Moderna, Vaxcyte Among The Biggest Losers

NegativePCVXOctober 6, 2026

Investors Business DailyNegative

Biotech Stocks Tumble, With Recent Winners Moderna, Vaxcyte Among The Biggest Losers

PCVX

MarketBeat

PCVX Stock Hits Fresh 52-Week High On Late-Stage Win In Adult Pneumonia Vaccine Race: Jefferies Says It Hit ‘Blue-Sky’ Case

PCVXOctober 5, 2026

Stocktwits

PCVX Stock Hits Fresh 52-Week High On Late-Stage Win In Adult Pneumonia Vaccine Race: Jefferies Says It Hit ‘Blue-Sky’ Case

PCVX

Proactive Investors

Vaxcyte shares surge on late-stage vaccine trial success

PositivePCVXOctober 5, 2026

Proactive InvestorsPositive

Vaxcyte shares surge on late-stage vaccine trial success

PCVX

Investors Business Daily

Vaxcyte Catapults After Going Toe-To-Toe With Pfizer, Merck In Vaccine Study

PositivePCVXOctober 5, 2026

Investors Business DailyPositive

Vaxcyte Catapults After Going Toe-To-Toe With Pfizer, Merck In Vaccine Study

PCVX

Reuters

Vaxcyte shares surge as pneumococcal vaccine succeeds in late-stage trial

PositivePCVXOctober 5, 2026

ReutersPositive

Vaxcyte shares surge as pneumococcal vaccine succeeds in late-stage trial

PCVX

Zacks Investment Research

4 Biotech Stocks With Key Clinical Readouts Expected This Fall

NeutralPCVXSeptember 22, 2026

Zacks Investment ResearchNeutral

4 Biotech Stocks With Key Clinical Readouts Expected This Fall

PCVX

News tone: automated (AI) classification of the article's content, not a price prediction.

About Vaxcyte, Inc. Common Stock

No description available.

SectorHealthcare

IndustryBiotechnology

Employees507

CEOMr. Grant E. Pickering M.B.A.

IPO DateJun 12, 2020

HeadquartersSan Carlos, CA

Key Executives

Name	Title	Year Born
Mr. Grant E. Pickering M.B.A.	Co-Founder, CEO & Director	1968
Mr. Andrew L. Guggenhime M.B.A.	President & CFO	1968
Mr. James T. Wassil M.B.A., M.S.	Executive VP, Chief Scientific Officer & COO	1969
Mr. Harpreet S. Dhaliwal M.B.A.	Chief Technical Operations Officer	1973
Dr. Jeff Fairman Ph.D.	Co-Founder & VP of Research	1964
Ms. Elvia Cowan	Senior VP of Finance & Chief Accounting Officer	1973
Mr. Jeff Macdonald	Executive Director of Investor Relations	—
Mr. David McAvoy J.D.	Chief Legal Officer, Chief Compliance Officer & Corporate Secretary	—
Ms. Whitney Jones	Chief People Officer	—
Ms. Janet Graesser	Senior Vice President of Corporate Affairs	—

Fundamentals

Valuation

Price-to-book value4.22

Profitability

Return on Equity-42.00%

Return on Assets-37.00%

EBITDA$-1.11B

Trading

Average volume2,129,899

Source: third-party data provider, as of November 13, 2026

Technical indicators

RSI 14: 59.53
MACD 12/26/9: 0.99
EMA 9 of MACD: 0.44
MACD histogram: 0.55
SMA 50: $62.13; Price above SMA 50
EMA 50: $62.39; Price above EMA 50
SMA 200: $57.58; Price above SMA 200
EMA 200: $57.21; Price above EMA 200

Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.

Analyst views

5 analyst ratings

Third-party analyst opinion, not a recommendation from Gotrade.

Analyst consensus:Buy

100% Buy

0% Hold

0% Sell

Analyst price target

Low: $89.00
Average: $117.20
High: $130.00

Cantor Fitzgerald

Carter Gould

Buy

Target price

$120.00

Needham

Joseph Stringer

Buy

Target price

$122.00

B of A Securities

Jason Gerberry

Buy

Target price

$130.00

Guggenheim

Seamus Fernandez

Buy

Target price

$125.00

BTIG

Thomas Shrader

Buy

Target price

$89.00

Seasonality

Monthly price change (%)

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2021											-21.9	+16.3
2022	-27.5	+20.5	+1.3	+1.7	-4.4	-4.1	+6.4	+14.6	-6.7	+80.0	+2.4	+5.4
2023	-3.9	-7.8	-10.1	+12.7	+2.6	-0.7	-2.3	+5.3	-4.0	-1.9	+7.9	+16.7
2024	+13.5	-2.3	-4.7	-9.3	+10.3	+4.5	+2.5	+2.8	+3.7	-8.0	-12.1	-10.6
2025	+6.0	-13.9	-47.6	+11.2	-7.8	-7.2	+3.1	-6.8	+14.1	+19.1	+15.8	+1.4
2026	+15.3	+7.6	-6.2	-2.2	-9.7	+18.9	-3.6	+13.5	-6.4	+10.7	+13.2

Compare stocks

PC

PCVX

Buy PCVX

Market cap

$10.86B

-

Price / Earnings ratio

-9.10

-

Price / Sales ratio

-

Dividend yield

0.00%

-

Average volume

2,129,899

-

Earnings per share

$-8.06

-

Vaxcyte, Inc. Common Stock (PCVX) Stock

Key stats

Compare with PCVX

Recent news

Wall Street Analysts See an 87.35% Upside in Vaxcyte (PCVX): Can the Stock Really Move This High?

Wall Street Analysts See an 87.35% Upside in Vaxcyte (PCVX): Can the Stock Really Move This High?

Wall Street Analysts Think Vaxcyte (PCVX) Could Surge 75.6%: Read This Before Placing a Bet

Wall Street Analysts Think Vaxcyte (PCVX) Could Surge 75.6%: Read This Before Placing a Bet

Biotech Stocks Tumble, With Recent Winners Moderna, Vaxcyte Among The Biggest Losers

Biotech Stocks Tumble, With Recent Winners Moderna, Vaxcyte Among The Biggest Losers

Vaxcyte's VAX-31 Meets All Primary Endpoints in Pivotal Phase III OPUS-1 Trial

Vaxcyte's VAX-31 Meets All Primary Endpoints in Pivotal Phase III OPUS-1 Trial

Technical indicators

Analyst ratings

Financials

Performance

Debt & Balance Sheet

Revenue to Profit

Earnings

Latest news

Wall Street Analysts See an 87.35% Upside in Vaxcyte (PCVX): Can the Stock Really Move This High?

Wall Street Analysts See an 87.35% Upside in Vaxcyte (PCVX): Can the Stock Really Move This High?

Wall Street Analysts Think Vaxcyte (PCVX) Could Surge 75.6%: Read This Before Placing a Bet

Wall Street Analysts Think Vaxcyte (PCVX) Could Surge 75.6%: Read This Before Placing a Bet

Biotech Stocks Tumble, With Recent Winners Moderna, Vaxcyte Among The Biggest Losers

Biotech Stocks Tumble, With Recent Winners Moderna, Vaxcyte Among The Biggest Losers

Vaxcyte's VAX-31 Meets All Primary Endpoints in Pivotal Phase III OPUS-1 Trial

Vaxcyte's VAX-31 Meets All Primary Endpoints in Pivotal Phase III OPUS-1 Trial

NVAX Stock Outruns Moderna As Vaxcyte’s Shot Clears A Late-Stage Test

NVAX Stock Outruns Moderna As Vaxcyte’s Shot Clears A Late-Stage Test

PCVX Stock Hits Fresh 52-Week High On Late-Stage Win In Adult Pneumonia Vaccine Race: Jefferies Says It Hit ‘Blue-Sky’ Case

PCVX Stock Hits Fresh 52-Week High On Late-Stage Win In Adult Pneumonia Vaccine Race: Jefferies Says It Hit ‘Blue-Sky’ Case

Vaxcyte shares surge on late-stage vaccine trial success

Vaxcyte shares surge on late-stage vaccine trial success

Vaxcyte Catapults After Going Toe-To-Toe With Pfizer, Merck In Vaccine Study

Vaxcyte Catapults After Going Toe-To-Toe With Pfizer, Merck In Vaccine Study

Vaxcyte shares surge as pneumococcal vaccine succeeds in late-stage trial

Vaxcyte shares surge as pneumococcal vaccine succeeds in late-stage trial

4 Biotech Stocks With Key Clinical Readouts Expected This Fall

4 Biotech Stocks With Key Clinical Readouts Expected This Fall

About Vaxcyte, Inc. Common Stock

Key Executives

Fundamentals

Valuation

Profitability

Trading

Technical indicators

Analyst views

Seasonality

Compare stocks

Market cap

Price / Earnings ratio

Price / Sales ratio

Dividend yield

Average volume

Earnings per share

Stocks in the same sector

FAQ

Trade Faster. Easier. Smarter.

#ReadyGoTrade